Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle.

ABSTRACT:

Background

Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor to preserve ventricular function and improve growth in these infants is unknown.

Methods

The Pediatric Heart Network designed a randomized, double-blind trial to compare outcomes in infants with single-ventricle physiology receiving enalapril or placebo. Neonates < or =45 days old were eligible. The primary outcome is weight-for-age Z-score at 14 months of age. Secondary outcomes include other measures of somatic growth, laboratory and functional measures of heart failure, developmental in

SUBMITTER: Hsu DT 

PROVIDER: S-EPMC2637409 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature